Compare Davita Inc (DVA) vs Honest Company Inc (HNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Honest Company Inc — how do they compare? Davita Inc trades at $179.32 (market cap $11.29B), while Honest Company Inc trades at $4.99 (market cap $533.20M). The key difference: Davita Inc is far larger — about 21.2× Honest Company Inc's market cap, and Honest Company Inc is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Honest Company Inc for 39 Days on average.
| DVA | HNST | |
|---|---|---|
Market Cap | $11.29B | $533.20M |
Volume | 582,204 | 1,990,155 |
Sector | Health | Consumer Staples |
52-Week High | $240.96 | $5.95 |
52-Week Low | $103.87 | $2.10 |
Typical Hold Time | 113 Days | 39 Days |
Enterprise Value | $24.01B | $436.81M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, with a bearish technical signal and neutral oscillators. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $4.02 beating expectations of $3.88. Revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026, though net margins have fluctuated. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents a mixed outlook with 43% analyst buy ratings and a $235.67 price target suggesting 33% upside. However, high debt levels (65.55% debt-to-asset ratio) and regulatory risks in healthcare weigh on fundamentals. The stock's current valuation at P/E 15 and P/S 0.88 appears reasonable relative to earnings growth potential, making it attractive for value investors despite near-term bearish technicals.
HNST trades at $4.93, down 1.99% today, with a bearish technical outlook despite recent earnings beat. The company shows mixed fundamentals with negative net income margin (-3.56%) and ROE (-6.87%), though Q2 2026 EPS of $0.04 exceeded expectations. Revenue declined to $371M in 2025, but operating cash flow improved to $15.1M. Analyst consensus is mixed with 30% buy ratings and $5.30 price target.
The stock faces headwinds from profitability challenges and competitive pressures, though strategic exits show early signs of margin improvement. Upside potential exists if the company sustains recent operational improvements, but investors should weigh the high P/E ratio of 48.83 against ongoing net losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →
